Trial · NCT00092677
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of MCE (Major Cardiovascular Events) | Entire follow-up (median = 4.35 years) | Composite endpoint of MCE consists of cardiovascular death, AVR (aortic valve replacement) surgery, CHF(congestive heart failure) as a result of progression of aortic stenosis, nonfatal MI (myocardial infarction), CABG (coronary artery bypass) surgery, PCI (percutaneous coronary intervention), hospitalized unstable angina, and nonhemorrhagic stroke |
| Secondary | Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of AVE (Aortic Valve Events) | Entire follow-up (median = 4.35 years) | Composite endpoint of AVE (aortic valve events) consists of AVR surgery, CHF (as a result of progression of AS), or cardiovascular death |
| Secondary | Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of ICE (Ischemic Cardiovascular Events) | Entire follow-up (median = 4.35 years) | Composite endpoint of ICE (ischemic cardiovascular events) consists of cardiovascular death, nonfatal MI, CABG, PCI, hospitalized unstable angina, and nonhemorrhagic stroke |
| Secondary | Change From Baseline in Peak Transaortic Jet Velocity | Baseline to End of follow-up (median = 4.35 years) or pre-aortic valve replacement | Mean change from baseline in peak transaortic jet velocity |
| Other | Cardiovascular Death | Entire follow-up (median = 4.35 years) | Number of participants that experienced cardiovascular death |
| Other | Aortic Valve Replacement (AVR) | Entire follow-up (median = 4.35 years) | Number of participants that experienced aortic valve replacement (AVR) |
| Other | Congestive Heart Failure (CHF) Due to Progression of Aortic Stenosis (AS) | Entire follow-up (median = 4.35 years) | Number of participants that experienced Congestive Heart Failure (CHF) due to progression of aortic stenosis (AS) |
| Other | Nonfatal Myocardial Infarction (MI) | Entire follow-up (median = 4.35 years) | Number of participants that experienced nonfatal myocardial infarction (MI) |
| Other | Coronary Artery Bypass Grafting (CABG) | Entire follow-up (median = 4.35 years) | Number of participants that experienced coronary artery bypass grafting (CABG) |
| Other | Percutaneous Coronary Intervention (PCI) | Entire follow-up (median = 4.35 years) | Number of participants that experienced percutaneous coronary intervention (PCI) |
| Other | Hospitalization for Unstable Angina | Entire follow-up (median = 4.35 years) | Number of participants that experienced hospitalization for unstable angina |
| Other | Nonhemorrhagic Stroke | Entire follow-up (median = 4.35 years) | Number of participants that experienced nonhemorrhagic stroke |
| Other | Death (Any Cause) | Entire follow-up (median = 4.35 years) | Number of participants that died (any cause) |
| Other | Percent Change in Time Weighted Average Total Cholesterol From Baseline to End of Follow-up | Baseline to End of follow-up (median = 4.35 years) | Mean percent change (time-weighted average over follow-up) from baseline: Time-weighted average calculated using values at week 8, week 24, year 1 and every 6 months with time interval (days) between 2 successive values used as the weighting factor. For the first follow-up value, the weight was the number of days from randomization. |
| Other | Percent Change in Time Weighted Average Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to End of Follow-up | Baseline to End of follow-up (median = 4.35 years) | Mean percent change (time-weighted average over follow-up) from baseline: Time-weighted average calculated using values at week 8, week 24, year 1 and every 6 months with time interval (days) between 2 successive values used as the weighting factor. For the first follow-up value, the weight was the number of days from randomization. |
| Other | Percent Change in Time Weighted Average High-density Lipoprotein Cholesterol (HDL-C) From Baseline to End of Follow-up | Baseline to End of follow-up (median = 4.35 years) | Mean percent change (time-weighted average over follow-up) from baseline: Time-weighted average calculated using values at week 8, week 24, year 1 and every 6 months with time interval (days) between 2 successive values used as the weighting factor. For the first follow-up value, the weight was the number of days from randomization. |
| Other | Percent Change in Time Weighted Average Triglycerides From Baseline to End of Follow-up | Baseline to End of follow-up (median = 4.35 years) | Mean percent change (time-weighted average over follow-up) from baseline: Time-weighted average calculated using values at week 8, week 24, year 1 and every 6 months with time interval (days) between 2 successive values used as the weighting factor. For the first follow-up value, the weight was the number of days from randomization. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00092677/registered